Clínica Médica

Resumo de evidência | Retirada de medicamentos em idosos convivendo com multimorbidade e polifarmácia.

5 Ago, 2022 | 16:38h

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Conteúdos relacionados:

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

 

---

Diretriz | Sintomas no trato urinário baixo masculino/hiperplasia prostática benigna.

5 Ago, 2022 | 16:35h

UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) – Canadian Urological Association Journal

Conteúdos relacionados: AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.

Podcast: LUTS, BPH, and Urinary Incontinence Triple Distilled – The Curbsiders

Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia – Cochrane Library

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis – Cochrane Library

Phosphodiesterase inhibitors for treatment of urinary problems in men with benign prostatic hyperplasia – Cochrane Library

Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial – The Lancet

 

---

Diretriz | Terapia de deprivação androgênica: eventos adversos e estratégias de tratamento.

5 Ago, 2022 | 16:32h

UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text) – Canadian Urological Association Journal

 

---

Estudo randomizado | Patiromer para tratamento de hiperpotassemia na insuficiência cardíaca com fração de ejeção reduzida.

5 Ago, 2022 | 16:27h

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial – European Society of Cardiology

 

Comentário no Twitter

No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y

— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022

 

---

Revisão | Tratamento da doença hepática relacionada ao álcool e suas complicações.

5 Ago, 2022 | 16:20h

Management of Alcohol-Related Liver Disease and Its Complications – Clinical Drug Investigation

Diretriz relacionada: Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines – Liver International

 

Comentário no Twitter (fio – clique para saber mais)

Excellent review about the Management of Alcohol-Related Liver Disease and Its Complications carried out by Dr. Cabezas.https://t.co/VICukJ3jEt
Key points:
1. It is still a stigmatized condition with underlying pathology.@AEEHLiver @sepdigestiva #LiverTwitter …

— Javier Crespo (@DrJavierCrespo) July 29, 2022

 

---

Diretrizes OMS sobre prevenção, diagnóstico, tratamento e cuidado de populações-chave para HIV, hepatite viral e DST.

4 Ago, 2022 | 14:31h

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations – World Health Organization

Comunicado de imprensa: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization

 

---

Impacto da doença pulmonar obstrutiva crônica e fatores de risco a ela atribuídos em 204 países e territórios, 1990-2019: resultados do Global Burden of Disease Study 2019.

4 Ago, 2022 | 14:28h

Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019 – The BMJ

Comunicado de imprensa: Chronic lung disease remains major public health problem – BMJ Newsroom

 

Comentário no Twitter

New research finds that despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index https://t.co/uUkQYCSmBY

— The BMJ (@bmj_latest) July 30, 2022

 

---

M-A | Agonistas receptores de GLP1 estão associados com risco aumentado de progressão de retinopatia em pacientes com diabetes tipo 2.

4 Ago, 2022 | 14:26h

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link para o resumo – $ para o texto completo)

Comentário: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues

 

---

Estudo de coorte retrospectiva | Síncope e o risco de subsequente de acidente automobilístico.

4 Ago, 2022 | 14:25h

Syncope and the Risk of Subsequent Motor Vehicle Crash: A Population-Based Retrospective Cohort Study – JAMA Internal Medicine (gratuito por tempo limitado)

Editorial: Driving Safety After an Acute Illness—This Is Our Lane – JAMA Internal Medicine (gratuito por tempo limitado)

 

Comentário no Twitter

"I fainted…am I safe to drive?" Study found that 9,223 drivers with an ED visit for syncope had subsequent crash risks no different than controls, suggesting more stringent driving restrictions might not be justified. https://t.co/T0GUJ63Nci

— JAMA Internal Medicine (@JAMAInternalMed) August 1, 2022

 

---

Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.

4 Ago, 2022 | 14:09h

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem

— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022

 

---